FIRST REPORT OF ERC-1671 (GLIOVAC) VACCINE USE IN GLIOBLASTOMA PATIENTS WITH RECURRENT DISEASE by Bota, Daniela A et al.
UC Office of the President
Recent Work
Title
FIRST REPORT OF ERC-1671 (GLIOVAC) VACCINE USE IN GLIOBLASTOMA PATIENTS WITH 
RECURRENT DISEASE
Permalink
https://escholarship.org/uc/item/4rj898p7
Journal
NEURO-ONCOLOGY, 14
ISSN
1522-8517
Authors
Bota, Daniela A
Pretto, Chrystel
Hantos, Peter
et al.
Publication Date
2012-10-01
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Abstracts 
vi48 NEURO-ONCOLOGY • o c To BER 2 o 1 2
IT-24. FIRST REPORT OF ERC-1671 (GLIOVAC) VACCINE USE 
IN GLIOBLASTOMA PATIENTS WITH RECURRENT DISEASE 
Daniela A. Bota', Chrystel Pretto2, Peter Hantos3, Florence M. Hofman4, 
Thomas C. ChenS, Jose A. Carrillo1, Virgil E. Schijns6, and Apostolos 
Apostolos Stathopoulos3; 1UC Irvine, Orange, CA; 2Epitopoietic Research 
Corporation, Namur, Belgium; 3Dept. of Neurosurgery, Arion Hospital, 
Arion, Belgium; 4Department of Pathology, University of Southern 
California, Los Angeles, CA; 5Department of Neurosurgery, University of 
Southern California, Los Angeles, CA; 6Cell Biology & Immunology Group, 
Wageningen University, Wageningen, Netherlands 
BACKGROUND: Recurrence of malignant gliomas following surgery, 
radiation therapy, and adjuvant chemotherapy is nearly universal. The 
only approved second-line treatment for malignant gliomas is bevacizurnab 
(Avastin), with estimated 6-month progression-free survival rates of 42.6% 
and an overall survival of 9.2 months. Ultimately, all GBM patients on bev­
acizumab experience relapse, and no other effective therapies are available. 
ERC-1671 aims to stimulate the patients' immune systems by including pa­
tients' glioblastoma tumors as lysates and cells as well as a heterologous com­
ponent generated from three different GBM donors. METHODS: Eligible 
patients who were over 18 years of age and had histologically confirmed 
World Health Organization (WHO) grade IV malignant glioma were 
treated under institutional review board (IRB)-approved protocols. Only pa­
tients for whom the standard-of-care regimens have failed were treated. 
Primary end points are toxicity and 6-month progression-free survival 
(PFS), and secondary endpoints are median overall survival (OS) and radio­
graphic response. RESULTS: To date, there has been a total of 4 patients 
enrolled, three on a phase 1 protocol at South Cliniques of Luxembourg­
Belgiurn, and one on a compassionate/single patient IND protocol at UC 
Irvine Medical Center. Median age was 52, with 2/4 female patients. The 
average Karnofsky performance status score (KPS) was 70 (50-80). Three pa­
tients are still alive; they are clinically and radiologically stable after an 
average of 7 (range: 3-11) weeks. One patient died of tumor progression 
and subsequent intra-cerebral hemorrhage 4 weeks after the first treatment. 
The toxicities were mild, with 2/4 patients developing grade-2 headaches 
and 4/4 grade-2 local erythema at the injection site. CONCLUSION: 
Based on the most recent studies, the 6-month progression free survival 
rate for patients with recurrent GBM that has become resistant bevacizumab 
is 16%. Our preliminary data suggest that ERC-1671 might be superior to 
active treatment with other chemotherapy agents in that clinical setting. 
Updated results will be presented at the Society for Neuro-Oncology 
meeting. 
